PDCD1 and myasthenia gravis: The most common irAEs in which autoantibodies have been described are found in 1) anti-CTLA-4 treatment (thyroid dysfunction), 2) anti-PD-1 treatment (myasthenia gravis/myopathy), and 3) anti-PD-L1 therapies (diabetic ketoacidosis), although with fewer reports than the former therapies.